New valve device for leaky heart valve under study in europe

NCT ID NCT05820516

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 100 adults with severe tricuspid regurgitation who receive the TricValve implant. Researchers will track survival, heart failure hospitalizations, kidney function, and quality of life for up to one year. The goal is to understand how well the device works and its effects on the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE TRICUSPID VALVE REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliero Universitaria Pisana

    RECRUITING

    Pisa, Pisa, 56124, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••